USP39

Across TCGA pan-cancer cohorts, USP39 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated USP39 data layer compared with 29 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher USP39 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated USP39 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where USP39 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.433	0.601	.009	17	view →
CCRCC	OS	Median	All	0.892	1.000	.004	16	view →
LUAD	DFS	Tertile	III,IV	0.899	0.418	.022	8	view →
UCEC	DFS	Quartile	All	0.797	0.970	.031	4	view →
HNSC	DFS	Median	III,IV	0.939	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

USP39–PDAC (OS)

Open the PDAC breakdown →